<DOC>
	<DOCNO>NCT00477815</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Radiolabeled monoclonal antibody , yttrium Y 90 ibritumomab tiuxetan , find cancer cell carry cancer-killing substance without harm normal cell . Drugs use chemotherapy , melphalan , work different way stop growth cancer cell , either kill cell stop dividing . A peripheral stem cell transplant use stem cell patient may able replace blood-forming cell destroy chemotherapy . Giving monoclonal antibody therapy together chemotherapy autologous peripheral stem cell transplant may kill cancer cell . PURPOSE : This phase I trial study side effect best dose yttrium Y 90 ibritumomab tiuxetan give together rituximab , melphalan , autologous peripheral stem cell transplant treating patient previously treat multiple myeloma .</brief_summary>
	<brief_title>Rituximab , Yttrium Y 90 Ibritumomab Tiuxetan , Melphalan , Autologous Peripheral Stem Cell Transplant Treating Patients With Previously Treated Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety rituximab , yttrium Y 90 ibritumomab tiuxetan , high-dose melphalan , autologous peripheral blood stem cell transplantation patient previously treat multiple myeloma . - Determine effect rituximab yttrium Y 90 ibritumomab tiuxetan clonotypic B-cells baseline B-cell recovery patient . Secondary - Determine response rate progression factor ( time progression , progression-free survival , duration response ) patient treat regimen . - Determine effect rituximab yttrium Y 90 ibritumomab tiuxetan clonal plasma cell blood marrow prior high-dose melphalan . OUTLINE : This dose-escalation study yttrium Y 90 ibritumomab tiuxetan . Patients receive rituximab IV follow dosimetry dose indium In 111 ibritumomab tiuxetan IV 10 minute day -22 . Patients acceptable biodistribution receive rituximab IV follow yttrium Y 90 ibritumomab tiuxetan IV 10 minute day -14 , high-dose melphalan IV 1 hour day -2 -1 , undergo autologous peripheral blood stem cell transplantation day 0 . Patients also receive sargramostim ( GM-CSF ) subcutaneously begin day 0 continue blood count recover . Cohorts 3-6 patient receive escalate dos yttrium Y 90 ibritumomab tiuxetan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Bone marrow , blood , urine sample collect baseline periodically study biomarker correlative study . After completion study treatment , patient follow every 3 month 5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Previously treat disease Candidate highdose chemotherapy melphalan autologous stem cell transplantation No definite evidence myelodysplasia pretreatment bone marrow morphology chromosome analysis ( e.g. , monosomy 7 ) Chromosome abnormality myeloma clone allow PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 2.0 mg/dL Alkaline phosphatase ≤ 3 time upper limit normal ( ULN ) AST ≤ 3 time ULN Creatinine ≤ 2 time ULN LVEF ≥ 45 % Corrected pulmonary diffusion capacity ≥ 50 % No uncontrolled infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active malignancy ( exception nonmelanoma skin cancer ) require myelosuppressive chemotherapy radiation therapy No HIV positivity PRIOR CONCURRENT THERAPY : More 3 week since prior myelosuppressive chemotherapy , except cyclophosphamide pulse stem cell collection ) No concurrent immunotherapy , radiotherapy , chemotherapy antimyeloma therapy Concurrent chronic corticosteroid dose prednisone ≤ 20 mg per day ( equivalent ) allow Concurrent adjuvant hormonal therapy ( e.g. , tamoxifen citrate leuprolide acetate ) allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>